George Kirigi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11889733/publications.pdf

Version: 2024-02-01

		1163117	1588992
8	440	8	8
papers	citations	h-index	g-index
8	8	8	539
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Sodium Stibogluconate (SSG) & Department of the SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial. PLoS Neglected Tropical Diseases, 2012, 6, e1674.	3.0	123
2	Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial. PLoS Neglected Tropical Diseases, 2010, 4, e709.	3.0	114
3	Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. PLoS Neglected Tropical Diseases, 2016, 10, e0004880.	3.0	66
4	Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials, 2011, 12, 166.	1.6	43
5	Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial. Clinical Infectious Diseases, 2019, 68, 1530-1538.	5.8	31
6	A new rural focus of cutaneous leishmaniasis caused by Leishmania tropica in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 381-387.	1.8	28
7	Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. Journal of Antimicrobial Chemotherapy, 2017, 72, 3131-3140.	3.0	23
8	Identification ofLeishmania tropicafrom micro-foci of cutaneous leishmaniasis in the Kenyan Rift Valley. Pathogens and Global Health, 2012, 106, 159-165.	2.3	12